Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellectar Biosciences filings document the regulatory record of a Delaware clinical biopharmaceutical company developing cancer therapies through its PDC platform. Current reports furnish quarterly and annual financial results, corporate updates, Regulation FD disclosures, and other events related to iopofosine I 131, CLR 125 and regulatory communications for its oncology programs.
Registration statements and material-event reports describe securities offerings, shelf registration activity, registered direct offerings, private placements, common stock, pre-funded warrants, milestone-based warrants and warrant exercise inducement transactions. The filing record also covers exhibit disclosures, Inline XBRL cover data, incorporation status, securities-law classifications and financing agreements that shape CLRB's public-company capital structure.
Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.6900 per share and expire on July 8, 2036. The award vests in full on July 8, 2027, subject to continued service through that date. Following this grant, Stefan holds 15,000 stock options directly.
Cellectar Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on July 7, 2026. Stockholders elected Class III directors Andrew Gu and Douglas J. Swirsky to new three-year terms. They approved an amendment to the 2021 Stock Incentive Plan to increase shares reserved for issuance by 2,000,000 shares of common stock. Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 and, on a non-binding advisory basis, approved executive officer compensation. In addition, stockholders approved the exercise of warrants to purchase up to 39,618,078 shares of common stock under Nasdaq rules, making a planned adjournment proposal moot.
Kolean Chad J reported acquisition or exercise transactions in this Form 4 filing.
Cellectar Biosciences CFO Chad J. Kolean received a grant of 92,000 stock options to buy common shares at $3.14 per share. The options were contingently granted on May 28, 2026, under Cellectar's amended 2021 Stock Incentive Plan and became effective after stockholders approved the plan on July 7, 2026.
The award vests over three years from May 28, 2026, with one-third vesting on the first anniversary and the remaining two-thirds vesting in 24 equal monthly installments thereafter. Following this grant, Kolean holds 92,000 stock options directly under this award.
Cellectar Biosciences director Frederick W. Driscoll received a grant of stock options representing 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. They vest in full on July 7, 2027, subject to his continued service, and this grant brings his reported option holdings from this award to 25,000 derivative securities.
Cellectar Biosciences director Asher Chanan-Khan received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. According to the terms, the entire grant will vest on July 7, 2027, provided he continues to serve through that date. Following this grant, his reported holdings include 25,000 stock options directly.
Cellectar Biosciences President & CEO James V. Caruso received a grant of stock options to acquire 250,000 shares of common stock at an exercise price of $3.14 per share. These options were contingently granted on May 28, 2026, subject to stockholder approval of the amended 2021 Stock Incentive Plan.
Stockholders approved the amended plan at Cellectar’s 2026 Annual Meeting of Stockholders on July 7, 2026, activating the grant. The options expire on May 28, 2036 and vest over three years, with one-third vesting on May 28, 2027 and the remainder vesting in 24 equal monthly installments thereafter.
Cellectar Biosciences director Andrew Gu received a grant of stock options as equity compensation. On July 7, 2026, he was awarded options covering 25,000 shares of common stock with an exercise price of $2.70 per share and an expiration date of July 7, 2036. According to the footnote, the option vests in full on July 7, 2027, provided he continues to serve the company through that date.
Cellectar Biosciences Chief Operating Officer Jarrod Longcor received a grant of stock options as equity compensation. The award covers 118,000 shares of common stock at an exercise price of $3.14 per share and expires on May 28, 2036.
The option was contingently granted on May 28, 2026 and became effective after stockholders approved the amended 2021 Stock Incentive Plan on July 7, 2026. It vests over three years, with one-third vesting on the first anniversary of May 28, 2026 and the remaining two-thirds vesting in 24 equal monthly installments thereafter.
Cellectar Biosciences director Douglas J. Swirsky received a grant of stock options covering 37,500 shares of common stock at an exercise price of $2.70 per share. The option vests in full on July 7, 2027, subject to his continued service, and expires on July 7, 2036. This is a compensation grant, with no open-market share purchases or sales reported.
Cellectar Biosciences director John Neis received a grant of stock options covering 25,000 shares of common stock. The options were awarded at an exercise price of $2.70 per share and expire on July 7, 2036. Following this grant, he holds options for 25,000 shares.
According to the footnote, the option vests in full on July 7, 2027, subject to his continued service through that vesting date. This is a compensation-related award rather than an open-market purchase or sale.